5-HT₆ receptor modulators: a patent update. Part 2. Diversity in heterocyclic scaffolds

Bibliography

• Ivashchenko AV, Ivanenkov YA, Tkachenko SE. 5-Hydroxytryptamine subtype 6 receptor modulators: a patent survey. Expert Opin Ther Pat 2010;20:1171-96
   PubMedGoogle Scholar
• Galenea Corporation, USA. Compounds and methods of use thereof. WO019738; 2011
   Google Scholar
• Medivation Technologies, Inc, USA. Azepino[4,5-b]indoles and methods of use. WO051503; 2010
   Google Scholar
• Medivation Technologies, Inc, USA. New 2,3,4,5-terahydro-1H-[4,3-b]indole compounds and methods of use thereof. WO094668; 2009
   Google Scholar
• Medivation Technologies, Inc, USA. New tetracyclic compounds. WO055828; 2009
   Google Scholar
• D2e, LLC, USA. Fluoro-containing derivatives of hydrogenated pyrido[4,3-b]indole derivatives with neuroprotective and cognition enhancing properties, process for preparing and use. WO038764; 2009
   Google Scholar
• Medivation Technologies, Inc, USA. Рyrido[4,3-b]indoles and methods of use. WO127177; 2010
   Google Scholar
• Kamal MA, Qu X, Yu QS, Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis. J Neural Transm 2008;115:889-98
   PubMed Web of Science ®Google Scholar
• Chen X, Fang L, Liu J, Zhan CG. Reaction pathway and free energy profile for butyrylcholinesterase-catalyzed hydrolysis of acetylcholine. J Phys Chem B 2011;115:1315-22
   PubMed Web of Science ®Google Scholar
• Hartmann J, Kiewert C, Duysen EG, Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity. J Neurochem 2007;100:1421-9
   PubMed Web of Science ®Google Scholar
• Medivation Technologies, Inc, USA. Pyrido[4,3-b]indoles containing rigid moieties. WO051501; 2010
   Google Scholar
• Medivation Technologies, Inc, USA. Pyrido[4,3-b]indoles and methods of use. WO019417; 2011
   Google Scholar
• Medivation Technologies, Inc, USA. New 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles and methods of use. WO014695; 2011
   Google Scholar
• Medivation Technologies, Inc, USA. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use. WO103433; 2011
   Google Scholar
• Medivation Technologies, Inc, USA. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use. WO103487; 2011
   Google Scholar
• Medivation Technologies, Inc, USA. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use. WO103485; 2011
   Google Scholar
• OOO «Innomed», Russia. Hydrogenated pyrido[4,3-b]indole, pharmaceutical composition and methods for the production and use thereof. WO014098; 2011
   Google Scholar
• Alla Chem, LLC, USA. Ligands for alpha-adrenoreceptors and of dopamine, histamine, imidazoline and serotonin receptors and the use thereof. WO082268; 2009
   Google Scholar
• Alla Chem, LLC, USA. Ligand with a broad spectrum of pharmacological activity, a pharmaceutical composition, a medicinal agent and a method of treatment. WO024717; 2010
   Google Scholar
• Ivashchenko AV, Ivashchenko AA, Savchuk NF. Ligand with wide range of simultaneous receptor activity, pharmaceutical composition, method of preparing said composition and medicinal agent. RU2374245; 2009
   Google Scholar
• Volk B, Gacsalyi I, Pallagi K, Optimization of (arylpiperazinylbutyl)oxindoles exhibiting selective 5-HT7 receptor antagonist activity. J Med Chem 2011;54:6657-69
   PubMed Web of Science ®Google Scholar
• Egis Gyogyszergyar Nyilvanosan Mukoedo Reszvenytarsasag, HU. Optically active 3- [(phenylpiperazin-1-yl)alkyl]-3-alkyl-oxindole derivatives having CNS activity. WO089616; 2010
   Google Scholar
• Janssen Pharmaceutica NV, Belg. Serotonin receptor modulators. WO059393; 2010
   Google Scholar
• Janssen Pharmaceutica NV, Belg. Рiperazin-1-yl trifluoromethyl-substituted-pyridine as fast dissociating dopamine 2 receptor antagonists. WO012758; 2010
   Google Scholar
• Instytut Farmakologii Polskiej Akademii Nauk, Pol. New 4,6-disubstituted 2-(4-methylpiperazin-l-yl)pyridine derivatives, a process for their preparation, pharmaceutical composition containing these compounds, their use, a method for modulating monoaminergic receptor activity and a monoaminergic receptor modulating agent. WO053388; 2010
   Google Scholar
• Schering Corp, USA. Gamma-secretase modulators for the treatment of Alzheimer's disease. WO108766; 2009
   Google Scholar
• Schering Corporation, USA. Gamma secretase modulators. WO073777; 2009
   Google Scholar
• Pfizer Inc, USA. Pyridinyl amides for treatment of CNS and metabolic disorders. US0197859; 2009
   Google Scholar
• Janssen Pharmaceutica NV, Belg. Preparation of 2-aminopyrimidine compounds as serotonin receptor modulators. WO053825; 2010
   Google Scholar
• Janssen Pharmaceutica NV, Belg. Substituted 6-(1-piperazinyl)pyridazines as 5-HT6 receptor antagonists. WO000456; 2010
   Google Scholar
• Abbott Gmbh & Co. KG, Germany. Quinoline compounds suitable for treating that respond to modulation of the serononin serotonin 5-HT6 receptor. WO019286; 2009
   Google Scholar
• Schering Corporation, USA. Gamma secretase modulators. WO073779; 2009
   Google Scholar
• Boehringer Ingelheim International G.m.b.H, Germany. Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture. WO007300; 2009
   Google Scholar
• Dainippon Sumitomo Pharma Co, Ltd, Japan. N-Acyl cyclic amine derivative or pharmaceutically acceptable salt thereof. WO111875; 2011
   Google Scholar
• Abbott Laboratories, USA. Modulators of 5-HT receptors and methods of use thereof. WO124042; 2010
   Google Scholar
• Abbott Laboratories, USA. Modulators of 5-HT receptors and methods of use thereof. WO135560; 2010
   Google Scholar
• Abbott Laboratories, USA. Modulators of 5-HT receptors and methods of use thereof. US0130382; 2011
   Google Scholar
• Ivachtchenko AV, Ivanenkov YA. 5-HT6 receptor antagonists: a patent update. Part 1. Sulfonyl derivatives. Expert Opin Ther Pat 2012;22:917-64
   PubMed Web of Science ®Google Scholar
• Pullagurla MR, Westkaemper RB, Glennon RA. Possible differences in modes of agonist and antagonist binding at human 5-HT6 receptors. Bioorg Med Chem Lett 2004;14:4569-73
   PubMed Web of Science ®Google Scholar
• Lopez-Rodriguez ML, Benhamu B, de la Fuente T, A three-dimensional pharmacophore model for 5-hydroxytryptamine6 (5-HT6) receptor antagonists. J Med Chem 2005;48:216-4219
   Google Scholar
• Ivachtchenko AV, Ivanenkov YA. 5HT(6) receptor antagonists: a patent update. Part 1. Sulfonyl derivatives. Expert Opin. Ther Pat 2012;22:917-64
   PubMed Web of Science ®Google Scholar